Fatigue News and Research

RSS

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Researchers investigated how emotions vary during travel and by travel mode

What mode of transportation makes you happiest? Clemson researchers investigated how emotions like happiness, pain, stress, sadness and fatigue vary during travel and by travel mode in a new study published in the journal Transportation.

30 May 2014

Vibration exercise may reduce pain in individuals diagnosed with fibromyalgia

A pilot study by Indiana University researchers found that whole-body vibration exercise may reduce pain symptoms and improve aspects of quality of life in individuals diagnosed with fibromyalgia.

30 May 2014

Midwest allergist records highest mold count for the 2014 allergy reporting season

The official allergy count for the Midwest today recorded the highest count for mold in the 2014 allergy recording season.

29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.

28 May 2014

Eisai launches new class of epilepsy treatment Fycompa in France

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.

22 May 2014

Bendamustine modestly efficacious but well tolerated in SCLC

Patients with relapsed or treatment-resistant small-cell lung cancer can achieve modest survival benefits with few side effects when treated with bendamustine, report US researchers.

21 May 2014

Managing menopausal symptoms in work life extremely difficult for working women

A new national survey released today by Working Mother Media and Pfizer on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.

21 May 2014

Circadian disruption during chemotherapy linked to greater fatigue and body weight loss, says study

The circadian system, better known as our biological clock, is responsible for coordinating all the processes that take place in our organism.

21 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

Study examines predictors and effects of testosterone therapy

Three new studies examining the predictors, effects and durability of testosterone therapy on men will be presented to reporters at the 109th Annual Scientific Meeting of the American Urological Association (AUA) during a special press conference in the Orange County Convention Center, Orlando, FL on Sunday, May 18 at 2:00 p.m. ET.

19 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

New results from a randomized trial published in the American Journal of Rhinology and Allergy demonstrate the benefits of in-office balloon dilation for sufferers of chronic sinusitis.

15 May 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

Fatigue News and Research

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Researchers investigated how emotions vary during travel and by travel mode

Vibration exercise may reduce pain in individuals diagnosed with fibromyalgia

Midwest allergist records highest mold count for the 2014 allergy reporting season

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

Eisai launches new class of epilepsy treatment Fycompa in France

Bendamustine modestly efficacious but well tolerated in SCLC

Managing menopausal symptoms in work life extremely difficult for working women

Circadian disruption during chemotherapy linked to greater fatigue and body weight loss, says study

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Study examines predictors and effects of testosterone therapy

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News